Pharmalot… Pharmalittle… Good Morning
2 CommentsBy Ed Silverman // May 3rd, 2011 // 7:02 am
Good morning, everyone, and nice to see you again. A sunny day is unfolding here on the Pharmalot corporate campus, where we hope we have solved our recent tech problems. We appreciate your patience. Meanwhile, we are brewing the usual cup of stimulation - our flavor today is Mocha Nut Fudge - and perusing the news of the world. Let us know if you hear something interesting. And, of course, have a productive and rewarding day…
Pfizer Earnings Rise On Lower Costs (Associated Press)
Novartis CEO Not Thrilled With Health Care Reform (Fortune)
Shanghai Pharma Raises $2.2B, Investors Include Pfizer (Bloomberg News)
Could Chemicals In Wine Improve Stent Performance? (Health Day)
Teva To Buy Japanese Generic Drugmaker (Globes)
FDA Approves Boehringer/Lilly Diabetes Drug (Pharma Times)
Parexel Cuts Guidance, Phase I Capacity After Weak Results (Outsourcing Pharma)
Docs Create Databases To Track Knee And Hip Replacements (Bloomberg News)
Bristol-Myers Recalls Coumadin Tablets (MedPage Today)
industry insider
The Parexel and CRO-wide story is significant because it shows universal pipeline weakness throught the pharmaceutical industry. In the robust days Phase I studies of any size had to be scheduled 3-6 months in advance to assure bed space.
industry insider
Ed, if Joe Jiminez is a typical hard charging CEO, I’m pretty sure that he used language stronger than “not thrilled” when describing US health care reform. Probably can’t be reprinted on a family-oriented blog.